Khiron Life Sciences Corp.

Hi everyone, and thank you for joining us. I'm Chris Naprawa, Chairman of Chiron's Board of Directors, and with me on our webcast today is Alvaro Torres, Chief Executive Officer, and Joel Friedman, Chief Financial Officer, as well as Francesca Ketterbach, European President. Before we start, there's a forward-looking statement. Please note that the following caution respecting the forward-looking statements, which is made on behalf of Chiron Life Sciences and all its representatives on this call. The statements made on this call will contain forward-looking information that involve risks and uncertainties, including those introduced by the COVID-19 pandemic. Actual results could differ materially from the conclusion, forecast, or projection in the forward-looking information. Certain material factors and assumptions are applied in drawing conclusion and making a forecast projection reflected in the forward-looking information. Additional information... About the material factors that could cause actual results to differ materially from the conclusions, forecasts, and projections in the forward-looking information. The material factors or assumptions that were applied in drawing a conclusion or making a forecast or projection reflected in the forward-looking information are contained in the Chiron Life Sciences filing with the Canadian Provincial Securities Regulators, which are available on CDAR and on CDAR at website at cdar.com. to provide a brief agenda. We'll start with a discussion of the quarter, where Alvaro will walk through some of the key highlights, and he turns it over to Joel to run through the financial results. After that, we'll dive into our guidance for 2022 for various growth scenarios there, including catalysts in each market that will drive growth. We'll wrap it up with a quick Q&A at the end. Now, with that, it is my sincere pleasure to turn it over to Alvaro Torres, CEO and Director.

Thank you, Chris. Thank you, everybody, for tuning in in this call. Four years ago, we founded this company with the goal of improving the quality of life of patients and consumers through the applied use of cannabis. As you know, Chiron is a B2C medical cannabis company, and we're focused on building brands. We're focused on building relationships with doctors, with patients, and insurance companies. And we're focused on generating value versus exporting commodities in a race to the bottom. When we think about being a B2C company in the international markets, that means thinking every day about building and generating demand. And to generate demand, we need to think about and solve for evidence, quality, and access. So without evidence, doctors will not prescribe medical cannabis. If the product quality is not good, and by that I mean consistent and safe, patients will not take on and continue the treatment. And without access, and I mean distribution, insurance coverage, good healthcare service, and governmental support, there is no market. Because of this, we created our business model. We are focused on servicing patients through great healthcare and using this as a platform to introduce patients and doctors to medical cannabis in a responsible manner. Our medical cannabis sales grew by 47% to 825,000 Canadian, maintaining a gross margin level of 88%. We are able to achieve this because we focus on creating high value for our patients. These results were largely because of the growth in Colombia and because the acceleration sales in Germany. And this rate of growth and the catalyst that I'll be talking about very soon in the immediate future gets us very excited about the path that we're creating. As you know, we acquired our clinics almost three years ago because we believe that to build the market we want to be in, we need a strategy to solve for these three issues. So today we see our clinics are generating data that is creating real-world evidence that is driving prescriptions and credibility. Because of this evidence, we're able to convince and persuade insurance companies and the governments that medical cannabis is not a fad, that medical cannabis is not a trend, that it's good for patients and it's less costly. That makes medical cannabis a disruptive force. And the clinics allows us to provide access to our pharmacy or partnering pharmacies through our conversations with insurance companies and through our service. And in the back of this, we're able to sell a great medication that is improving the quality of life of patients. When I look back at our Q2 results, and I think they continue to showcase that we're on the right track and with the right acceleration because, one, we are growing in the medical cannabis sector in every market we are entering. Two, that our B2C strategy is producing strong profitability. Three, that our vertical integration strategy is the best path towards growth and that we need to deploy this clinic strategy in our target markets wherever possible, as fast as possible. And fourth, that Europe is becoming a significant part of our medical cannabis operations. We are, without a doubt, the leading company in the Colombian medical cannabis domestic market. I think this is thanks to our vertical integration strategy with Serenio, the goodwill of our products, and the increasing number of patients that are benefiting from our treatment. The last few months have encouraged us to continue moving forward with this strategy and deploy our clinics in Mexico, in Peru, in Brazil, and in the U.K. We know how to prescribe medical cannabis responsibly. We know how to persuade doctors into prescribing because we are creating a level of evidence that very few companies can talk about, particularly in our regions. We know how difficult it is to persuade physicians to prescribe cannabis, and we have created an ecosystem of evidence and education that needs to be deployed faster in every market that we're targeting. Very soon, we will be making our first publication in an indexed medical journal, showcasing the real-world evidence we have collected with more than 1,400 patients in Colombia, all of them with Chiron-made products. We plan to launch more publications for different conditions in the coming months. I think you can agree with me that this will create a level of credibility worldwide that very few companies can enjoy, and that will drive more prescriptions across all our markets. We are executing plans to finish this year with sales in Mexico, Colombia, Peru, Brazil, UK, and Germany. Our clinic strategy will certainly be a big part of this, which is all about creating demand, generating real-world evidence, developing new products, and increasing profitability. And, of course, we have to do this while we continue to be mindful of our cash investment, our collection of revenues from our clients, our management of expenses, and the well-being of our team and the patients who are responsible for the successful path that we are creating. With that all being said, I'd like to ask Joel, our CFO. to provide more details in the Q2 financials before I come back with Francie, talk about a little bit of operational highlights, our guidance that we've talked about in MD&A, and a quick Q&A session. So with that, thank you, please, Joel.

Joel, you're on mute. Joel, you're on mute.